Successful Afatinib Therapy after Resistance to EGFR-TKI in a Patient with Advanced Adenosquamous Cell Lung Cancer

被引：4
作者：
Tamura, Tomohiro [1 ]
Kagohashi, Katsunori [1 ]
Satoh, Hiroaki [1 ]
机构：
[1] Univ Tsukuba, Mito Med Ctr, Div Resp Med, Mito, Ibaraki 3100015, Japan
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2015年 / 38卷 / 06期
关键词：
Lung cancer; Afatinib; Resistance; EGFR-TKI; Adenosquamous cell lung cancer; Rechallenge; MUTATION;
D O I：
10.1159/000431351
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：316 / +
页数：2
相关论文
共 4 条
  • [1] Bordi Paola, 2014, Tumori, V100, pe20, DOI 10.1700/1430.15832
  • [2] The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
    Kim, Youngwook
    Ko, Jeonghun
    Cui, ZhengYun
    Abolhoda, Amir
    Ahn, Jin Seok
    Ou, Sai-Hong
    Ahn, Myung-Ju
    Park, Keunchil
    [J]. MOLECULAR CANCER THERAPEUTICS, 2012, 11 (03) : 784 - 791
  • [3] Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment
    Kuiper, Justine L.
    Heideman, Danielle A. M.
    Wurdinger, Tom
    Grunberg, Katrien
    Groen, Harry J. M.
    Smit, Egbert F.
    [J]. CLINICAL LUNG CANCER, 2015, 16 (01) : 60 - 66
  • [4] Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib
    Schuler, Martin
    Fischer, Juergen R.
    Grohe, Christian
    Guetz, Sylvia
    Thomas, Michael
    Kimmich, Martin
    Schneider, Claus-Peter
    Laack, Eckart
    Maerten, Angela
    [J]. ONCOLOGIST, 2014, 19 (10) : 1100 - 1109
1